Tyra Biosciences, Inc. (TYRA): R&D Expense
$102.93M
Year ended 2025-12-31
$126.32M
Trailing 12 months to 2026-06-30
+33.8%
3-year compound annual growth
+70.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $102.93M | +28.5% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $80.08M | +28.1% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $62.52M | +45.4% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $43.01M | +108.4% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $20.64M | +186.5% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $7.20M | n/a | 2022-03-03, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $102.93M | +28.5% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $12.74M | -69.7% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $117.33M | -3.0% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $184.70M | +54.6% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Neurogene Inc. (NGNE) | 2025-12-31 | $75.01M | +23.1% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $51.52M | +34.1% |
Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗